Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
A patient's perspective
In 2011 Les Halpin was diagnosed with motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS). Since his diagnosis, Les has been committed to accelerating the development, approval and licensing of novel therapies for people with life threatening illnesses. Two years ago he also founded Halpin Neurosciences, a privately owned biotechnology company, to focus on accelerating the development of therapies for MND. In 2012 Les formed a campaigning organisation, ‘Access to Medicine’ http://www.accesstomedicine.co.uk/, a platform to open up a wider debate about the lack of drug development for people with life threatening illnesses.
A very good friend of mine died of motor neuron disease (MND) 20 years ago, as did a non-familial uncle 15 years ago. They received no therapies which could slow the disease progress, and from my perspective not a lot has changed since that time. This disease has affected me in a profound way, leaving me unable to walk and to use my limbs for everyday activities, affecting my speech, swallowing and breathing and robbing me of independence. The single licensed drug for MND, riluzole, is having no measurable impact on the progression of my disease nor on my quality of life.
The current drug approval process is cumbersome—it can take years, and requires extremely large and risky investment, to take a drug from the development stage through to Phase III and beyond. As an example, no new drug has been approved for MND since riluzole, almost 20 years ago. The drug regulatory regime, therefore, must change in order to help people with life threatening and rare illnesses. For such individuals, the ‘risk-return ratio’ is different compared with patients with more benign conditions and drug regulations should be adapted to allow such people the opportunity to try out new combinations of drugs. Currently drug companies do not …
Funding The Wellcome Trust.
Competing interests None.
Provenance and peer review Not commissioned; internally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Tragic choices
- Using telehealth in motor neuron disease to increase access to specialist multidisciplinary care: a UK-based pilot and feasibility study
- Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial)
- Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues
- Epidemiology of ALS in Korea using nationwide big data
- Amyotrophic lateral sclerosis and the innate immune system: protocol for establishing a biobank and statistical analysis plan
- Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China
- A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland
- The management of motor neurone disease
- Pathophysiological insights into ALS with C9ORF72 expansions